Mauna Kea Technologies SA (0P5I.L)
| Previous close | 0.3360 |
| Open | 0.3400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.3400 - 0.3400 |
| 52-week range | 0.3400 - 0.7630 |
| Volume | |
| Avg. volume | 442 |
| Market cap | 10.437M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3530 |
| Earnings date | 30 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
PARIS, October 04, 2024--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
- Business Wire
Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio
PARIS & BOSTON, September 16, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication1 in the peer-reviewed Journal of Thoracic Disease of new ground-breaking clinical results demonstrating the efficacy of its needle-based Confocal Laser Endomicroscopy (nCLE) technology for the characterization of peripheral lung cancer and preparat
- Business Wire
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio®
PARIS & BOSTON, September 10, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the American Foregut Society (AFS), a leading society of gastroenterologists and surgeons collaborating to improve patient outcomes of several conditions, including esophageal disease, has formally requested that health insurance providers update their medica
